An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this program and the company’s R&D, leading to the layoff of about 50% of employees.In connection with the restructuring, Dublin-based Theravance said Tuesday that a committee comprised of members of its board of directors is reviewing strategic alternatives that could include a sale of the company.The Th...
Continue Reading
Sign up for FREE to read the full article and access 134K+ alternative investment headlines.
Alternative Investment News